Literature DB >> 8043040

Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo.

D C Shugars1, M S Smith, D H Glueck, P V Nantermet, F Seillier-Moiseiwitsch, R Swanstrom.   

Abstract

The nef genes of the human immunodeficiency viruses type 1 and 2 (HIV-1 and HIV-2) and the related simian immunodeficiency viruses (SIVs) encode a protein (Nef) whose role in virus replication and cytopathicity remains uncertain. As an attempt to elucidate the function of nef, we characterized the nucleotide and corresponding protein sequences of naturally occurring nef genes obtained from several HIV-1-infected individuals. A consensus Nef sequence was derived and used to identify several features that were highly conserved among the Nef sequences. These features included a nearly invariant myristylation signal, regions of sequence polymorphism and variable duplication, a region with an acidic charge, a (Pxx)4 repeat sequence, and a potential protein kinase C phosphorylation site. Clustering of premature stop codons at position 124 was noted in 6 of the 54 Nef sequences. Further analysis revealed four stretches of residues that were highly conserved not only among the patient-derived HIV-1 Nef sequences, but also among the Nef sequences of HIV-2 and the SIVs, suggesting that Nef proteins expressed by these retroviruses are functionally equivalent. The "Nef-defining" sequences were used to evaluate the sequence alignments of known proteins reported to share sequence similarity with Nef sequences and to conduct additional computer-based searches for similar protein sequences. A gene encoding the consensus Nef sequence was also generated. This gene encodes a full-length Nef protein that should be a valuable tool in further studies of Nef function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8043040      PMCID: PMC237849     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations.

Authors:  P Balfe; P Simmonds; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells.

Authors:  T M Niederman; J V Garcia; W R Hastings; S Luria; L Ratner
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

4.  Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells.

Authors:  S Anderson; D C Shugars; R Swanstrom; J V Garcia
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

6.  The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4.

Authors:  J V Garcia; J Alfano; A D Miller
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells.

Authors:  J Kaminchik; N Bashan; A Itach; N Sarver; M Gorecki; A Panet
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

8.  Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease.

Authors:  T McNearney; Z Hornickova; R Markham; A Birdwell; M Arens; A Saah; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Constitutive expression of the nef gene suppresses human immunodeficiency virus type 1 (HIV-1) replication in monocytic cell lines.

Authors:  Y Tsunetsugu-Yokota; S Matsuda; M Maekawa; T Saito; T Takemori; Y Takebe
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

View more
  99 in total

1.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation.

Authors:  Marcel Pietrek; Melanie M Brinkmann; Ilona Glowacka; Anette Enlund; Anika Hävemeier; Oliver Dittrich-Breiholz; Michael Kracht; Marc Lewitzky; Kalle Saksela; Stephan M Feller; Thomas F Schulz
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

5.  Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension.

Authors:  Sharilyn Almodovar; Rob Knight; Amanda A Allshouse; Sarah Roemer; Catherine Lozupone; Daniel McDonald; Jeremy Widmann; Norbert F Voelkel; Robert J Shelton; Edu B Suarez; Kenneth W Hammer; Cecile Goujard; Nicola Petrosillo; Gerald Simonneau; Priscilla Y Hsue; Marc Humbert; Sonia C Flores
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-17       Impact factor: 2.205

6.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Tracey M Filzen; Kathleen L Collins
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity.

Authors:  Christelle Brégnard; Alessia Zamborlini; Marjorie Leduc; Philippe Chafey; Luc Camoin; Ali Saïb; Serge Benichou; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques.

Authors:  I H Khan; E T Sawai; E Antonio; C J Weber; C P Mandell; P Montbriand; P A Luciw
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.

Authors:  C Aiken
Journal:  Virology       Date:  1998-08-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.